Pociredir hydrochloride (Cat No.:I044411) is a selective, orally active Toll-like receptor 8 (TLR8) agonist developed for antiviral and immuno-oncology research. It stimulates innate immune responses by activating monocytes and dendritic cells, leading to the production of pro-inflammatory cytokines and enhanced antigen presentation. Pociredir hydrochloride has shown promise in chronic hepatitis B virus (HBV) therapy by promoting immune-mediated viral clearance. Its immunomodulatory activity also supports exploration in cancer immunotherapy. The hydrochloride salt improves stability and bioavailability, making it suitable for in vivo and clinical studies targeting immune dysfunction.